Kaneq Bioscience Overview
- Year Founded
-
2012

- Status
-
Private
- Latest Deal Type
-
2ndary - Private
Kaneq Bioscience General Information
Description
Developer of early-stage compounds intended to treat metabolic diseases and cancer. The company's compounds develop a protein tyrosine phosphatase1B ("PTP-1B") inhibitor for treating type 2 diabetes mellitus and therapies for hypertension and diabetes, enabling pharmaceutical companies to get high-value molecules for validated targets and discover several marketed drugs.
Contact Information
Corporate Office
- 2900 -1000 De La Gauchetière ouest
- Montreal, Quebec H3B 4W5
- Canada
Corporate Office
- 2900 -1000 De La Gauchetière ouest
- Montreal, Quebec H3B 4W5
- Canada
Kaneq Bioscience Valuation & Funding
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
3. Secondary Transaction - Private | 01-Jan-2020 | Completed | Generating Revenue | |||
2. Early Stage VC (Series A) | 01-Jan-2014 | Completed | Generating Revenue | |||
1. Early Stage VC | 22-Jan-2013 | Completed | Generating Revenue |
Kaneq Bioscience FAQs
-
When was Kaneq Bioscience founded?
Kaneq Bioscience was founded in 2012.
-
Where is Kaneq Bioscience headquartered?
Kaneq Bioscience is headquartered in Montreal, Canada.
-
What industry is Kaneq Bioscience in?
Kaneq Bioscience’s primary industry is Drug Discovery.
-
Is Kaneq Bioscience a private or public company?
Kaneq Bioscience is a Private company.
-
What is Kaneq Bioscience’s current revenue?
The current revenue for Kaneq Bioscience is
.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »